| Anthony F Waechter, MD | |
|
1425 S Main St., Walnut Creek, CA 94596-5318 | |
| (925) 295-4000 | |
| Not Available |
| Full Name | Anthony F Waechter |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1425 S Main St., Walnut Creek, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811075922 | NPI | - | NPPES |
| 00A826450 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A82645 (California) | Primary |
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Kibow® Biotech Inc, a pioneering probiotic company in gut modulation with its novel "Enteric Dialysis®" technology platform, is celebrating its 22-year anniversary on October 1st, 2019.
More women than men die of heart failure. The reason is that only 50 per cent of the heart failure cases among women are caused by having a heart attack, which can be treated with modern methods.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling "dirty mice."
› Verified 6 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
Kibow® Biotech Inc, a pioneering probiotic company in gut modulation with its novel "Enteric Dialysis®" technology platform, is celebrating its 22-year anniversary on October 1st, 2019.
More women than men die of heart failure. The reason is that only 50 per cent of the heart failure cases among women are caused by having a heart attack, which can be treated with modern methods.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling "dirty mice."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony F Waechter, MD 4565 Sweetgale Dr, San Ramon, CA 94582-5013 Ph: (925) 968-1516 | Anthony F Waechter, MD 1425 S Main St., Walnut Creek, CA 94596-5318 Ph: (925) 295-4000 |
News Archive
Kibow® Biotech Inc, a pioneering probiotic company in gut modulation with its novel "Enteric Dialysis®" technology platform, is celebrating its 22-year anniversary on October 1st, 2019.
More women than men die of heart failure. The reason is that only 50 per cent of the heart failure cases among women are caused by having a heart attack, which can be treated with modern methods.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling "dirty mice."
› Verified 6 days ago
Brook Andrew Woolley, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1425 S Main St, Emergency Medicine Department, Walnut Creek, CA 94596 Phone: 925-295-5100 | |
Malcolm C Johnson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Alice Decker Hunter, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Seigfred P. Jalalon, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1450 Treat Blvd # 160, Walnut Creek, CA 94597 Phone: 925-296-9000 | |
Theodore Ira Kloth, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Stephanie Carlson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 | |
Michael R. Lozano, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 |